Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings

Sage Therapeutics (SAGE) PT Lowered to $90 at Wedbush, Following Earnings

May 4, 2021 11:32 AM EDT

Wedbush analyst Laura Chico lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $90.00 (from $98.00) while maintaining a Outperform rating.

... More

Sage Therapeutics (SAGE) PT Raised to $189 at Goldman Sachs, Following Earnings

May 4, 2021 11:11 AM EDT

Goldman Sachs analyst Salveen Richter raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $189.00 (from $187.00) while maintaining a Buy rating.

... More

SAGE Therapeutics (SAGE) Tops Q1 EPS by 27c, Revenues Miss

May 4, 2021 7:16 AM EDT

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.64), $0.27 better than the analyst estimate of ($1.91). Revenue for the quarter came in at $1.58 million versus the consensus estimate of $2 million.

Sage started 2021 with significant advances across our depression, neurology and neuropsychiatry franchises,... More